Dihydroartemisinin-piperaquine is a fixed-dose artemisinin-based combination treatment.
Some antimalarials have altered pharmacokinetics in pregnancy. Pregnant women in the …

Pregnant women are particularly vulnerable to malaria. The pharmacokinetic properties of
antimalarial drugs are often affected by pregnancy, resulting in lower drug concentrations …

The pharmacokinetic properties of piperaquine were investigated in 12 pregnant and 12
well-matched, non-pregnant women receiving a three-day oral fixed dose combination …

The tolerability, safety, and disposition of dihydroartemisinin (DHA) and piperaquine (PQ)
were assessed in 32 pregnant (second/third trimester) and 33 nonpregnant Papua New …

Objective To determine the pharmacokinetic properties of dihydroartemisinin (DHA)
following oral artesunate treatment in women with recrudescent multi-drug resistant …

Background Pregnancy is associated with an increased risk of developing a malaria
infection and a higher risk of developing severe malaria. The pharmacokinetic properties of …

Abstract Background The World Health Organization endorses the use of artemisinin-based
combination therapy for treatment of acute uncomplicated falciparum malaria in the second …

Malaria is a serious parasitic infection, which affects millions of people worldwide. As
pregnancy has been shown to alter the pharmacokinetics of many medications, the efficacy …

Dihydroartemisinin–piperaquine is being increasingly used as a first–line artemisinin
combination treatment for malaria. The aim of this study was to describe the pharmacokinetic …

Background Malaria in pregnancy increases the risk of maternal anemia, abortion and low
birth weight. Approximately 85.3 million pregnancies occur annually in areas with …